AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).

Read More »

GSK, Lilly join $350bn wave of U.S. drug investments amid tariff threat

Investing.com-- GSK (LON:GSK) and Eli Lilly (NYSE:LLY) announced fresh U.S. manufacturing investments on Tuesday, joining a wave of global drugmakers ramping up domestic capacity as the Trump ...

Read More »

GSK and Eli Lilly Announce Billions in U.S. Manufacturing Investments Amid Tariff Concerns

GlaxoSmithKline (GSK) and Eli Lilly are making major U.S. manufacturing commitments as global pharmaceutical companies expand domestic operations in response to possible tariffs on imported medicines.

Read More »

Drugmakers have pledged $350 bln in US investments after tariff threat - WSJ

According to the WSJ’s tally, more than a dozen drugmakers have pledged over $350 billion in U.S. investments this decade, partly to offset potential tariff costs.

Read More »

GSK’s new antibiotic for urinary tract infections gets U.K. approval

Investing.com -- GSK plc (LON:GSK) has received U.K. regulatory approval for its oral antibiotic treatment for uncomplicated urinary tract infections (UTIs), marking the first new type of oral ...

Read More »